This article reviews key advances in ion-selective electrode technology that have made potentiometric measurements of ionized calcium (Ca2) reliable and precise. Our use of two second-generation Ca2 analyzers (Radiometer ICA1 and NOVA 8) made possible uninterrupted service as volume increased to 31 640 patient tests in 1985. The lower results on the NOVA 8 were adjusted upwards to match those of the ICA1 to give identical results. Both analyzers were evaluated under working conditions of high volumes and multiple operators to establish downtime, electrode life, and costs. We have classified all Ca2 analyzers into first-, intermediate-, and second-generation instruments, the better to understand their differences. Results for large numbers of patients' sera were shown to be systematically different when any two analyzers were compared. These differences are the consequence of each manufacturer's unique choices of the following: (a) the matrix of the calcium calibration solutions, (b) the type and configuration of the reference electrode, and (C) the salt-bridge solution. Elimination of each analyzer's biases will require agreement on a reference system that defines the accuracy of Ca2 measurements on serum, plasma, or whole blood. The sound analytical performance of today's second-generation Ca2 analyzers has allowed us to exploit the inherent superiority of Ca2 over total calcium (CaT) measurements in the daily care of patients. We report on the preference of Ca2 over Ca1 by physicians at our hospital since the introduction of second-generation Ca2 analyzers. Therefore, we state unequivocally from our very satisfactory experience over the past five years that Ca2 is a clinical laboratory test whose time has come! The measurement of ionized calcium (Ca2+)1 j was ordered 10 and cardiovascular/ transplantation surgery programs for the kidney, heart, and liver.
Received May 14, 1986 (pro-reviewed) ; accepted May 20, 1986. 1986. As shown in Figure 1 , this preference by our physicians for Ca2 measurements became clear about a year after its introduction as a daily service test five years ago. The experience gained in providing 31 000 Ca2 measurements per year and in helping colleagues to interpret the meaning of results on individual patients is the reason for our advocacy of this basic test in the evaluation of calcium metabolism. This article will review the following topics:
I. Rationale for measuring Ca2 vs CaT II. Classification and availability of Ca2 analyzers ifi. Experience with two second-generation Ca analyzers IV. Analysis of the clinical utility of Ca2 at our hospital While the analytical reliability of Ca2 measurements is the primary focus of this article, we must also emphasize the importance of pre-analytical factors (position, time, and meals) and post-analytical considerations (age, limits, and expected values) that must be taken into consideration to make the interpretation of Ca2 results meaningful to the physician.
I. Rationalefor MeasuringCa2 vs CaT
The separation of calcium in human serum into a diffusible fraction and a non-diffusible protein-bound fraction was reported by Rona and Takahashi in 1911 (2) surement of Ca2 with the frog heart-muscle bioassay in the early 1930's, the diffusible fraction had been further subdivided into "free" calcium ions and calcium complexed to anions (3). Their experimental observations left no doubt that Ca2 was the "biologically active" fraction of primary physiological and clinical importance in blood and other body fluids (4) . Subsequent studies on healthy individuals and on patients with parathyroid disorders showed unequivocally that the parathyroid glands regulated the concentration of Ca2 and established the central role of Ca2 in human calcium metabolism (5) . While McLean and Hastings advocated Ca2 over Cap measurements in patients, they discouraged the use of the bioassay method in the clinical laboratory. This paradox was resolved by their providing a nomogram for calculating Ca2 from CaT and total protein. However, they noted that this estimation of Ca2 was based on several assumptions and was only a first approximation, because "other variables, including pH, temperature, albumin to globulin ratio, magnesium, and citrate, are known to influence the ionization of calcium in thesefluids" (4) . Neither this original nomogram nor later ones that replaced total protein with albumin and added pH have seen wide use for calculating Ca2 in clinical laboratories (6) .
McLean and Hastings' brilliant work led many investigators to try to develop chemical and physical separatory techniques to measure this "active" free-calcium fraction in blood (7, 8) , but few of these methods were used in clinical service laboratories. The need for quantitative calcium measurements in blood was served by a variety of CaT methods3 (9) . Dependence on Ca1 as the sole means of evaluating calcium status in patients started to change in 1967 after the publication of Ross's paper entitled "calcium selective electrode with liquid ion-exchanger" (10). During the 1965-70 period when the first ion-selective electrode (ISE) was in the early stages of development, Moore explored the clinical applications of Ca2 measurements in patients (8, 11-13). His work showed the feasibility of making rapid ISE measurements of Ca2 directly in serum, plasma, or whole blood. The calcium ISE of the electrochemical cell, like frog muscle, responded only to "free" calcium ions in the blood; it was not subject to the variability of calcium bound to albumin or complexed to anions. Moore concluded that the measurement of Ca2 by ISE was more useful in clinical medicine than that of CaT. (23, 24) . Unfortunately, we were forced to discontinue offering Ca2 measurements for patient care because the Orion 99-20 system was not rugged and precise enough for continuous daily use in testing. Our have now compared five other analyzers with the ICA1 and find they all give essentially a parallel response, although lower by 0.02 to 0.04 mmol/L. These have included the NOVA 2,7, and 8, the AVL 980, and a prototype of the Ciba-Corning Model 634.
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Ca2, pH, Nat, K Ca2, pH, Ca2 (7.4) major problem seemed to be lot-to-lot changes in the quality of both the liquid ion-exchanger and the nitrocellulose membranes. In retrospect, we expected too much of an early ISE technology that was undergoing major changes and frequent field modifications, as subsequent reports have documented (8,25-27).
Intermediate-generation Ca2 analyzers were introduced from 1978 until 1982 and all used the neutral carrier sensor of Simon (see ref.
18). The classification of"intermediate" is
used to identi1r the lack of a concurrent pHmeasurement at 37#{176}C. Consequently, these intermediate Ca2 analyzers do not have the ability to normalize Ca2 to pH 7.4 (Ca27.4) as many workers have recommended (7, 8, 24, (28) (29) (30) . All second-generation Ca2 analyzers listed in Table 1 make simultaneous Ca2 and pH measurements at 37#{176}C on every sample under the semi-automatic control of a microprocessor which internally calculates the Ca274 and then displays Ca2, pH, and Ca274 results. The importance of these simultaneous pH and Ca2 measurements is shown in the bottom half of Figure 2 , the distribution of pH values for 250 hospitalized adult patients who had Ca2 requested in mid-December 1985. Note that 31% (14% low, 17% high) of these venous-serum samples had a pH value that fell beyond the reference limits of 7.35 and 7.45. By plotting the actual Ca2 at the mecaured pH and then connecting to the Ca274 value by a line, one can see a two-dimensional representation of the alternative ways of reporting Ca2. The question of which of these parameters need to be reported to physicians is unresolved (29) (30) (31) (32) . Table 2 lists the operational and analytical performance characteristics of four second-generation Ca2 analyzers. The trend in the recently developed Ca2 analyzers is towards smaller sample size, quicker display of results, and reduced overall cycling time (33, 34) . D951) ; however, they noted overestimation at low (0.5 mmol/L) and underestimation at high (2 mmol/L) concentrations. Our experience was less favorable because microclots were much too frequent.
Ill. Experiencewith Two Second-GenerationCa2
As workloads grew to 35-40 tests/day (1000 testa/28-day period in Figure 1) , we noted that recalibration with aqueous reference materials and repeat values on serum became less reproducible. This poorer performance was attributed to "protein build-up" owing to the heavy volume of patient testing. Intensified cleaning and preventative maintenance did not improve the reproducibility, but addition of a surfactant to the rinse solution did. Further changes in all plastic parts in contact with serum and a new sodium formate bridge solution also helped to improve performance, even with a steadily increasing workload.
We also noted that the longevity of the Ca2 electrode tips decreased as workloads grew. As seen in Table 3 , the interval between tip changes in the three heavily used service laboratory ICA1's ranged from nine to 52 days and averaged 25 days. In contrast, the tip-life in the less heavily used R&D instrument ranged from nine to 84 days and averaged 51 days. This difference in tip-life is to be expected, because each cycle causes minor leaching of the vital ionexchanger and solvent from the PVC membrane. Thus, longevity is more a function of the number of cycles to which each tip is exposed rather than of the time in days. To examine this relationship in greater detail, we counted all cycles for Ca2 testing during February 1985 and found, as shown in Table 4 , that only 44% of cycles represented reportable patient tests. Thus, the 31 640 patient tests of fiscal year 1985 translated to a grand total of about 70000 cycles. We estimated from yearly purchase orders that we used 150 membranes and 50 electrode tips. These figures suggest that membranes need to be changed after 500 cycles and tips after 1500 cycles to be sure an ISE is fully functional. From these data on tip cycle-life and knowledge of yearly reagent and calibrator usage, we can make a analytical cycles.
calculated to be $0.26 per cycle (exclusive of labor, repair, and capital costs) or about $0.57/patient sample. The analytical performance of each of the three ICA1's used for patient testing at workloads averaging 70 patient tests/day (160 cycles/day) was monitored daily in FY '85 with our pooled human serum internal quality-control material (35) . The standard deviation (SD) for CaS* each month ranged from 0.010 to 0.024 mmol/L at a mean concentration near 1.20 mmol/L. The median SD for all 36 months was ±0.016 mmoLfL, giving a CV of 1.3% for our day-to-day long-term intralaboratory Ca2 testing. Boink and Sprokholt recently reported (21) on the interlaboratory performance observed during a large survey of Ca2 results involving 24 separate ICA1's in European and American laboratories (including our four ICA1's). The Ca2 result for a bovine serum sample had a mean and SD of 1.069 and 0.026 mmoL'L, respectively, and a CV of 2.5% for a network of 16 laboratories located in a wide geographical area.
To estimate the systematic bias of the ICA1 when measuring serum, we used the Henderson equation (36) to calculate the liquid-liquid junction potential (E3) of the ICA1 calibrator and serum. The residual E3 suggested that results for patients' serum samples are systematically low by 5.0%. Our experimental studies suggested that values for serum are 6.2% low as measured in the ICA1 (22 Figure 3 . Knowing that all analyzers 5These expendable costscan be decreasedif the laboratory makes the rinse solutions and calibrators. Labor costs vary from lab. to lab., but we estimate it is $0.50/cycle or about $1.00/chargedpatient test. Likewise, firm estimates of repair and capital costs that depend on test volume are quite varied. However, our current estimate is $0.10/cycle. have their unique biases, we simply adjusted the NOVA 8 outputs upwards electronically to give results that matched those of the ICA1 (see the table in lower right of Figure 3) , because the reference intervals in this hospital were firmly established by four years of use of the ICA1's. This "adjusted" NOVA 8 was placed in service alongside two ICA1's during the summer of 1985 so that it might be evaluated under similar working conditions of heavy daily testing by many analysts. In so doing, we achieved a long-sought goal of redundancy for service testing with two second-generation Ca2 analyzers, replacement parts, reagents, and calibrators supplied by totally independent U.S. and Danish sources. Furthermore, the 90-s cycle time of the NOVA 8's, as compared with 180 s for the ICA1, shortened the time needed to perform Ca2 testing. The trade-off for this increase in throughput was a 350-FL sample volume for the NOVA 8 vs only 120 L for the ICA1. However, sample volume has been a secondary consideration in adults, although this too is changing (37,38), and is mitigated when an analyzer such as the ICA1 is available for smaller samples (e.g., from premature infants).
Our daily operational experience with the NOVA 8 showed that it required the same fastidious care and regular maintenance as all other ISE devices. We became aware of a subtle relationship between the plastic tubing and the calcium sensor ("inner element") that caused results to change as either or both components aged. Aqueous controls were relatively insensitive to these changes and we, like others (39), found it necessary to monitor the daily analytical performance with serum-based control materials in order to determine when to install and (or) accept a new "inner element" or to replace tubing and other components.
A long-term study of the longevity of the NOVA 8 "inner elements" is in progress and present data suggest that they shouldbereplacedafter6flo ± 5ocyclesifafullresponseto all serum samples is to be assured. Our cost estimate for expendables for the NOVA 8 is $0.27 per cycle (exclusive of labor and capital costs)or about $0.45 per patient sample. 6 The analytical performance of the NOVA 8 when used daily for patient testing at overall workload rates of 70 patient tests per day (160 cycles per day) was also monitored with our internal quality-control pool. (22) .
IV. Analysis of the Clinical Utility of Ca2 on Our Wards
Basal conditions: For hospitalized patients, we request that the patient remain supine after an overnight fast until an anaerobic venous serum sample is drawn between 7 and 9 a.m. This deliberate choice of preparation, timing, and sampling defines the basal conditions and helps to avoid Ca2 changes due to posture, diurnal variation, and recent food ingestion. The anaerobic sample can be held and centrifuged at room temperature for up to 4 h before changes in Ca2 concentration are seen. For longer storage intervals of days or months, we hold serum off the clot at 4#{176}C or -60 #{176}C, to minimize pH and other metabolic
changes.
Reference values: The Ca274 limits for adults under basal conditions are from 1.17 to 1.29 mmol/L for the Radiometer ICA1's and the "adjusted" NOVA 8 analyzers (29) . Younger men and older women tend slightly towards the higher limit, while younger women tend slightly towards the lower limit. Due to diurnal variation, which causes a peak in Ca2 between 7 to 9 a.m., the values for specimens drawn at other times are slightly lower. However, the upright position causes shifts of fluids into the extravascular spaces of the lower extremities and the serum from blood drawn from an arm vein of an individual who is upright will consistently give a slightly higher Ca2 value. For adults who are ambulatory prior to venipuncture, we find the upper reference limit (Ca27.4) is increased by 0.04 mmoIJL over the prone/fasting value of 1.29 to 1.33 mmol/L.7 Food ingestion usually increases Ca2, but this varies with intake and timing, and we have seen lower values in a few individuals
(24).
The reference intervals for the different pediatric age groups vary greatly in respect to the relatively narrow adult range. Values <1.00 mmol/L are characteristic of prema#{176}The major expendable costs on the NOVA 8 are for electrodes, not solutions and calibrators. There would probably be some savings if the reagents were made in-house, but no information on the formulation is readily available.
7We usethe reference values recommendedby Siggaard-Andersen et al. (29) with modification of the upper reference limit for ambulatory adults to 1.33 mmol/L (97.5 percentile) after study in May 1983 of 604 outpatients' samples. tare infants, and the degree of hypocalcemia correlates with the gestational age (40). Healthy newborns show about the same mean value as adults during the first 24 postnatal hours, but with much wider limits. The mean and limit values move progressively higher during the succeeding two weeks. Given the rapid physiological shifts in Ca2, water, and other electrolytes that can occur just before and after the birth of sick newborns, the lack of well-defined pediatric reference values has made difficult the clinical interpretation of Ca21 results in premature and newborn infants. Values for young children continue to be somewhat higher than those for adults until after the pubertal growth spurts. The reference values merge with those for adults in the mid to late teens for females and in the late teens to early twenties for males.
Abnormal results in hospitalized patients: The importance of the simultaneous measurement of pH with Ca2 in patients' samples has already been shown. The slight shift in the distribution to the higher pH values (see Figure 2) suggests a tendency to lose small amounts of CO2 during sample handling, thus lowering the calcium ion concentration in vitro from what it was in vivo. To offset this systematic bias towards an artifactually lowered Ca21, we routinely report to the wards only the Ca2174, but all three values are recorded and made available when requested. The bold dashed line in Figure 2 represents the vector of changing Ca2 values as CO2 is either lost or gained in a serum that starts at the physiological mean concentration of 1.23 mmol of Ca2 per liter and a pH of 7.40. We would prefer to plot all three results on a report form such as that shown in Figure 2 , but computerized formats currently limit the routine reporting to only the Ca2'74. Table 5 summarizes the abnormal Ca274 results that were reported to the wards and intensive-care units of medicine, surgery, and pediatrics for the months of December 1983 and February 1985. Note that the abnormal values in outpatients were at overall rates of between 3 and 6%, as expected. However, we were s9rised at the 39% (31% low, 8% high) abnormal rate for Ca + results on the inpatient wards in December 1983. Closer inspection of these later data reveals that the highest abnormal rates were as follows: Recovery Room at 69% (50% low, 20% high), Surgical ICU/C5W at 64% (64% low, 0% high), Renal Transplantation ward at 59% (52% low, 7% high), Medical ICU/C8W at 58% (52% low, 6% high), and Pediatric Newborns at 57% (39% low, 18% high). Most wards had many more low values than high ones and we believe that these low values, apart from pediatrics, are related to the following: (a) the very transient hypocalcemia associated with citrate binding of Ca2 owing to use of multiple units of ACD blood, (b) the more-prolonged hypocalcemia associated with albumin changes in end-stage renal disease, malignancy, and malabsorption, and (c) as-yet-unexplained but frequently encountered low values associated with the "critically ill" patients as described by Drop and associates (41,42) . There is need for wider recognition of the severe Ca2 hypocalcemia in these extremely sick patients and for better understanding of the help that calcium replacement therapy might give them.
Re-examination of the abnormal rates on the same wards in February 1985 showed 41% (31% low, 10% high) and except for the Surgical ICU/C5W showed just about the same proportions between low and high abnormalities. In retrospect, we now know that the 57% abnormal rate on the pediatric wards in December 1983 was distorted because the 
Discussion
The experimental and clinical findings of McClean and Hastings demonstrated unequivocally in the mid-1930s that Ca2 rather than CaT is of primary physiological and clinical importance (3) (4) (5) . Over the past 50 years, numerous investigators have repeatedly confIrmed and extended this central role of Ca2 (7, 8, 24, (45) (46) (47) .
Given the opportunity to order Ca21 as easily as CaT determinations, physicians at our hospital have shown a preference for the use of Ca2 over CaT, as shown in Figure 1 . However, when Ca2+ testing was first made available five years ago, physicians initially were reluctant to use the test because the new reference intervals appeared strange and the magnitude of the Ca2 abnormalities usually found in association with diseases of calcium metabolism were unfamiliar to them. Despite a special effort by the laboratory staff that made Ca2 assay readily available 24 hours a day in a way exactly parallel to pH and blood gas determinations, it took about a year for the volume of Ca21 testing to equal that of Car. In fiscal year 1985 we performed 31640 Ca2 measurements on patients' sera vs 6915 CaT determinations. This 5:1 ratio had increased to 10:1 in February 1986 at a time when total clinical chemical test volume was dropping slightly because of fewer inpatient admissions! This recent successful experience in offering Ca2 as a routine daily service test stands in stark contrast to our prior failure in the 1970's. At that time we were forced to discontinue the test when the world's only manufacturer of calcium ISE analyzers was unable consistently to deliver the vital ion-exchanger. In contrast, the technology behind today's calcium ISE testing has matured to such a degree that eight original equipment manufacturers with facilities located in six different countries are producing Ca2 analyzers. Calcium ISE technology now rests upon a substantial body of scientific knowledge produced over the last two decades by a number of academic and industrial research groups in the United States and Europe (18). Translation of this ISE technology into meaningftil Ca2 measurements on patients' samples has required the integration of unique chemical ISE skills with mechanical and electronic engineering capacities within the industry (48). As a direct result of these industrial efforts, several state-of-the-art second-generation Ca2 analyzers are now available. At least two of these analyzers have been shown to be rugged and precise under the daily working conditions of very high volume and continuous use by many analysts in our laboratory.
There now exists a substantial cadre of knowledgeable clinical laboratory scientists and physicians who are advocates of Ca2 They have organized scientific meetings to exchange their ideas and experiences with colleagues and have also promoted lively interactions with their academic and industrial peers (49) (50) (51) (52) (53) (54) . These interactions have progressively refined our understanding of the basic ISE technology as it is found in today's Ca + analyzers and have continuously added to our clinical knowledge concerning the importance of Ca2 measurements. This cadre of advocates is now asking the question: "Why do so few service laboratories offer Ca2, given that the ISE technology is so dependable and the accumulated clinical experience with Ca2' over CaT measurements is so uniformly favorable?" Some of our thoughts about that question are as follows:
First, the move to offer Ca2' measurements in service laboratories must be stimulated by the physicians who deal with the clinical problems of calcium metabolism. However, Car has been the focal clinical test for many years and is readily available at a low cost as part of widely used chemistry screening proffles. Car is the normative test by current medical standards, and physicians are satisfied with the use of CaT, especially for outpatient evaluations, because it readily uncovers abnormally high values. Furthermore, the interpretation of results is backed by years of personal experience and many publications. In short, it is difficult to switch to Ca2 because the CaT is so entrenched, so readily available, and so well perceived by physicians because it serves their office needs well.
In contrast to outpatients, more and more of today's hospitalized patients are quite ill on admission because of delays due to DRG and other preadmission clearance hurdles and cost-containment policies. As a consequence, these sicker patients and their attending physicians need the immediate availability of accurate analytical information in order to establish the diagnosis quickly and initiate definitive therapy without delay (in part to remain within the predetermined average length of stay for Medicare and other third-party payers). In sicker patients, it is clear that Car measurement by itself is a poor indicator of the calcium status, even when quantified quickly with an accurate method. A patient's serum albumin concentration must also be known if the CaT result is to be meaningfully interpreted. Many clinicians regularly do correct Car values for changes in albumin, but the effects of several other variables such as pH and various anions is not revealed by the CaT determination. For example, the physiological hypocalcemia associated with citrate loads from multiple transfusions with "ACD" blood, or from an abnormally high lactate or bicarbonate concentration is of great importance in many critically ill patients, yet is obscured by CaT. In contrast, the ISE measurement of Ca2 tracks the hypocalcemia when any anion complexes the free calcium.
Second: Another reason for slow acceptance of Ca2 testing may be the fact that earlier Ca2' analyzers have failed in too many clinical laboratories. We had a vivid memory of our earlier failure and in 1981 we were reluctant to offer the test again as a routine daily service. We knew from the literature that the second-generation Ca2' analyzers were much improved, but we needed to make our own evaluations to be certain that these instruments functioned well under hard and continuous daily use by many analysts in our own service laboratory. Two Ca2 analyzers have met that performance goal. Today, in 1986, manufacturers and their allied companies have worldwide marketing and service organizations to provide for the timely distribution of analyzers, reagents, and replacement parts needed for maintenance and repair. A half-dozen instruments are now exhibited at national meetings and, as shown in Table 2 , the newly introduced analyzers require smaller sample volumes and respond quicker with shorter total cycle times. Together, Tables 1 and 2 suggest that competitive market forces are continuing to stimulate improvements in both the analytical performance and productivity of Ca2 analyzers. Third: All Ca2' analyzers are plagued with the need to replace the vital Ca2' ISE, which causes unpredictable downtime despite sound preventative maintenance. The problem of frequent electrode dysfunction and replacement of ISE's is characteristic of most types of ISE analyzerssuch as pH/blood gas and Na/K analyzers-that must be online continuously without any interruption in vital service. We have emphasized some of the unique failure modes that are related to high volumes of patients' samples. However, the information that has helped us to understand and resolve some of these repetitive problems is a clear working knowledge of the wide variability in the lifetime to be expected in the key calcium ISE element. A few ISE sensors simply never work, a few more fail within the first few days, but most elements function well for hundreds of analytical cycles.
We have stressed the need for redundancy in instruments and supplies; we must stress that redundancy in welltrained personnel is also necessary. Knowledgeable technical personnel must be available to perform the testing and to oversee the quality of the results by assuring that analyzers are used and maintained correctly. By providing such redundancy of instrumentation and personnel, we have been able to offer Ca2' services on a 24 h per day basis, without interruption, for the last four years.
Fourth, the introduction of Ca2 testing may be slow because of the lack of agreement on standardization. Even a brief review of the reference values published for Ca2 reveals that incompatability of results is a serious problem. For example, the lower reference limit in the serum of adults of 0.96 mmol/L obtained with some first-generation analyzers as compared with the 1.12 to 1.17 mmo)JL of second-generation Ca2 analyzers not only suggests a nonNernstian response with the early ISEs but also reflects inter-instrumental differences between the more recently introduced analyzers. Fortunately, very few of the earlier devices are still in service, and the magnitude of the differences found between second-generation Ca2 analyzers is only about ± 0.03 mmol/L in our comparisons. These differences are due primarily to calcium binding to buffers in the calibrator solutions and (or) to the residual liquid-liquid junction potential between the calibrators and serum. Groups in Europe (21, 56) and the U.S.A. (22) are actively working to develop reference methods and primary reference solutions to help eliminate these systematic errors in Ca2 measurements. The need for agreements on a reference system for Ca2 that defines the accuracy of these valuable measurements is now recognized (56) (57) (58) (59) .
At present, we seem to have a "catch 22" situation. Many physicians might like to request Ca2 testing, yet have had little or no practical experience with Ca2 as compared with CaT because the test is not available. On the other hand, clinical laboratories do not offer the test because doctors do (47)] 
